StockNews.com Lowers AxoGen (NASDAQ:AXGN) to Hold

StockNews.com cut shares of AxoGen (NASDAQ:AXGN) from a buy rating to a hold rating in a report published on Monday.

Separately, Cantor Fitzgerald restated an overweight rating and issued a $12.00 price objective on shares of AxoGen in a report on Friday, January 19th.

AxoGen Price Performance

AXGN opened at $5.87 on Monday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.23 and a current ratio of 3.43. The stock has a market capitalization of $256.55 million, a PE ratio of -11.74 and a beta of 1.07. The stock’s 50 day moving average price is $7.58 and its 200-day moving average price is $7.49. AxoGen has a 52-week low of $3.45 and a 52-week high of $10.83.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Tuesday, March 5th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.11. AxoGen had a negative net margin of 12.99% and a negative return on equity of 22.18%. The business had revenue of $42.92 million for the quarter, compared to the consensus estimate of $42.70 million. On average, equities research analysts predict that AxoGen will post -0.46 EPS for the current year.

Insider Buying and Selling at AxoGen

In other news, CEO Karen L. Zaderej sold 39,280 shares of the business’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $7.68, for a total transaction of $301,670.40. Following the sale, the chief executive officer now owns 1,124,565 shares in the company, valued at approximately $8,636,659.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CEO Karen L. Zaderej sold 39,280 shares of AxoGen stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $7.68, for a total transaction of $301,670.40. Following the completion of the transaction, the chief executive officer now directly owns 1,124,565 shares in the company, valued at $8,636,659.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Erick Wayne Devinney sold 4,578 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $7.68, for a total value of $35,159.04. Following the completion of the sale, the insider now owns 165,661 shares in the company, valued at approximately $1,272,276.48. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 111,201 shares of company stock valued at $928,054. 7.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AxoGen

Several large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets increased its stake in AxoGen by 8.6% during the 1st quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after purchasing an additional 1,651 shares in the last quarter. Rice Hall James & Associates LLC bought a new stake in shares of AxoGen during the first quarter valued at approximately $1,236,000. Keeley Teton Advisors LLC raised its holdings in AxoGen by 135.3% in the 4th quarter. Keeley Teton Advisors LLC now owns 84,725 shares of the medical equipment provider’s stock worth $579,000 after acquiring an additional 48,725 shares during the last quarter. Panagora Asset Management Inc. lifted its position in AxoGen by 69.8% in the 4th quarter. Panagora Asset Management Inc. now owns 165,461 shares of the medical equipment provider’s stock valued at $1,130,000 after acquiring an additional 68,001 shares in the last quarter. Finally, M&T Bank Corp boosted its stake in AxoGen by 18.2% during the 4th quarter. M&T Bank Corp now owns 56,780 shares of the medical equipment provider’s stock valued at $388,000 after purchasing an additional 8,744 shares during the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.